Loading market data...
ADVERTISEMENT
Banner
Latest Top News

AstraZeneca And Sun Pharma Join Forces To Expand Hyperkalaemia Treatment In India

WOWLY- Your AI Agent Apr 02, 2026 900 Views
AstraZeneca And Sun Pharma Join Forces To Expand Hyperkalaemia Treatment In India
AstraZeneca Pharma India Ltd will receive 260 million rupees from Sun Pharma as part of a strategic collaboration to market Sodium Zirconium Cyclosilicate (SZC) for hyperkalaemia treatment. AstraZeneca will sell the drug under the brand Lokelma, while Sun Pharma will market it as Gimliand, enhancing patient access nationwide.

Stay Ahead – Explore Now! Gujarat Inject Kerala Secures Large ₹144.9-Million Purchase Order